Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtrer
1.
Medicine (Baltimore) ; 103(24): e38298, 2024 Jun 14.
Article de Anglais | MEDLINE | ID: mdl-38875421

RÉSUMÉ

INTRODUCTION: Most adrenal tumors are benign and primary adrenal malignancies are relatively rare. Primary adrenal lymphoma (PAL) is a very rare and highly aggressive malignant tumor with unknown etiology, atypical clinical symptoms, nonspecific imaging manifestations, difficult disease diagnosis and poor prognosis. CASE REPORT: This case report details a 42-year-old woman who was admitted to the hospital with a 1-year-old bilateral adrenal mass and 1-month-old left upper abdominal pain. Enhanced CT of the abdomen showed a right adrenal nodule and a large occupying lesion in the left adrenal region, with a high probability of pheochromocytoma. Intraoperatively, a huge tumor measuring about 12*12*10 cm was found in the left adrenal region, infiltrating the left kidney, spleen and pancreatic tail. Postoperative pathology: lymphocytes were found in the renal capsule and subcapsule, lymphocytes were found in the pancreas; lymphocytes were found in the spleen. Consider a tumor of the lymphohematopoietic system, possibly lymphoma. CONCLUSION: This case demonstrates that primary adrenal diffuse large B-cell lymphoma (PADLBCL) is highly aggressive, has a poor prognosis, is prone to recurrence, has poor therapeutic outcomes, and is difficult to diagnose. Clinicians should consider the possibility of PADLBCL when encountering huge adrenal-occupying lesions and consider chemotherapy before surgery. Reducing the tumor size before surgery is a more favorable therapeutic approach, thus prolonging the patient life and improving the quality of survival.


Sujet(s)
Tumeurs de la surrénale , Lymphome B diffus à grandes cellules , Humains , Femelle , Lymphome B diffus à grandes cellules/anatomopathologie , Lymphome B diffus à grandes cellules/diagnostic , Tumeurs de la surrénale/anatomopathologie , Tumeurs de la surrénale/diagnostic , Tumeurs de la surrénale/chirurgie , Adulte , Tomodensitométrie , Glandes surrénales/anatomopathologie , Glandes surrénales/imagerie diagnostique , Glandes surrénales/chirurgie
2.
Infect Immun ; 88(10)2020 09 18.
Article de Anglais | MEDLINE | ID: mdl-32747601

RÉSUMÉ

The cytolethal distending toxin B subunit (CdtB) induces significant cytotoxicity and inflammation in many cell types that are involved in the pathogenesis of postinfectious irritable bowel syndrome (PI-IBS). However, the underlying mechanisms remain unclear. This study tested the potential role of Rab small GTPase 5a (Rab5a) in the process. We tested mRNA and protein expression of proinflammatory cytokines (interleukin-1ß [IL-1ß] and IL-6) in THP-1 macrophages by quantitative PCR (qPCR) and enzyme-linked immunosorbent assays (ELISAs), respectively. In the primary colonic epithelial cells, Cdt treatment induced a CdtB-Rab5a-cellugyrin association. Rab5a silencing, by target small hairpin RNAs (shRNAs), largely inhibited CdtB-induced cytotoxicity and apoptosis in colon epithelial cells. CRISPR/Cas9-mediated Rab5a knockout also attenuated CdtB-induced colon epithelial cell death. Conversely, forced overexpression of Rab5a intensified CdtB-induced cytotoxicity. In THP-1 human macrophages, Rab5a shRNA or knockout significantly inhibited CdtB-induced mRNA expression and production of proinflammatory cytokines (IL-1ß and IL-6). Rab5a depletion inhibited activation of nuclear factor-κB (NF-κB) and Jun N-terminal protein kinase (JNK) signaling in CdtB-treated THP-1 macrophages. Rab5a appears essential for CdtB-induced cytotoxicity in colonic epithelial cells and proinflammatory responses in THP-1 macrophages.


Sujet(s)
Toxines bactériennes/toxicité , Mort cellulaire/effets des médicaments et des substances chimiques , Inflammation/immunologie , Protéines G rab5/immunologie , Apoptose/effets des médicaments et des substances chimiques , Toxines bactériennes/métabolisme , Cellules cultivées , Cytokines/immunologie , Cellules épithéliales , Extinction de l'expression des gènes , Humains , Inflammation/anatomopathologie , Macrophages , Liaison aux protéines , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/immunologie , Synaptogyrines/métabolisme , Cellules THP-1 , Protéines G rab5/génétique , Protéines G rab5/métabolisme
3.
Am J Transl Res ; 8(12): 5580-5590, 2016.
Article de Anglais | MEDLINE | ID: mdl-28078028

RÉSUMÉ

The roles of 5-hydroxytryptamine (5-HT) and spinal N-methyl-D-aspartic acid receptor 2B (NR2B) in visceral hypersensitivity were investigated. A rat model with irritable bowel syndrome (IBS) was established by intracolonic injections of acetic acid onpost-natal days 8-21. Rats were randomly divided into five groups: normal intact (control) group, IBS model group, Ro25-6981-treated IBS rats (Ro25-6981, a NR2B antagonist) group, amitriptyline-treated IBS rats (amitriptyline, a 5-HT antagonist) and Ro25-6981 plus amitriptyline-treated IBS rats (Ro25-6981+amitriptyline) group. The expressions of 5-HT, NR2B, 5-HT2AR, 5-HT7R, SERT, TNF-α and IL-1ß in colon, dorsal root ganglion (DRG) and hypothalamus, respectively, were measured by Immunohistochemical staining, Real-Time Reverse Transcription-PCR and Western blotting. Our results showed increased DRG and hypothalamus expression of 5-HT, NR2B, 5-HT2AR, 5-HT7R in IBS model group and decreased expression of those in Ro25-6981 and amitriptyline alone or both treatment groups. Moreover, SERT expression was decreased in colorectal, DRG and hypothalamus of ISB model rats, but increased by Ro25-6981 and amitriptyline alone or both treatments. Ro25-6981 and amitriptyline treatment also decreased colorectal expression of TNF-α and IL-1ß induced by IBS model. In conclusion, activation of 5-HT and NR2B may play a crucial role in visceral hypersensitivity in irritable bowel syndrome in rats.

4.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 34(6): 656-60, 2014 Jun.
Article de Chinois | MEDLINE | ID: mdl-25046944

RÉSUMÉ

OBJECTIVE: To evaluate the efficacy and safety of Yigan Fupi Decoction (YFD) in the treatment of irritable bowel syndrome with diarrhea (IBS-D) patients. METHODS: A randomized controlled clinical trail was carried out in patients with IBS-D. All patients were randomly assigned to the treatment group (58 cases, treated with YFD) and the control group (58 cases, treated with Pinaverium Bromide Tablet). The treatment course was 4 weeks for all patients. The total effective rate, the stool property and state, the quality of life (QOL), and TCM syndrome efficacy were assessed by IBS bowel symptom severity scale (IBS-BSS), IBS defecation state questionnaire (IBS-DSQ), IBS quality of life questionnaire (IBS-QOL), and traditional Chinese medicine pattern curative effect scoring system (TCM-PES) before and after treatment. RESULTS: There was no statistical difference in the total effective rate between the two groups (82.76% vs. 77.59%, P > 0.05). The treatment group was superior in the total IBS-BSS integral to the control group (P < 0.05). The total effective rate of improving the stool property was better in the treatment group than in the control group (81.03% vs. 72.41%, P < 0.05). Besides, the number of days for emergent defecation among 10 days was less in the treatment group than in the control group (P < 0.05). The improvement of the total IBS-QOL integral and the total integral of TCM syndrome were better in the treatment group than in the control group (P < 0.01). The total effective rate of TCM-PES was better in the treatment group than in the control group (84.48% vs. 70.69%, P < 0.05). CONCLUSION: YFD was effective in the treatment of IBS-D patients of Gan-qi invading Pi syndrome, and could effectively relieve bowel symptoms, improve the stool property and the defecation frequency, elevate their QOL, and attenuate Gan-qi invading Pi syndrome with favorable safety and compliance.


Sujet(s)
Diarrhée/traitement médicamenteux , Médicaments issus de plantes chinoises/usage thérapeutique , Syndrome du côlon irritable/traitement médicamenteux , Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Morpholines/usage thérapeutique , Qualité de vie , Résultat thérapeutique
5.
Heart Lung ; 43(1): 45-7, 2014.
Article de Anglais | MEDLINE | ID: mdl-24157381

RÉSUMÉ

A 41-year-old woman with a history of asthma arrived at the emergency room of our hospital with dyspnea. The electrocardiogram showed no specific results. Echocardiography defects revealed an obvious decrease in the left ventricular systolic function and enlargement of the left chamber. We initially considered her condition to be dilated cardiomyopathy. However, she had eosinophilia in the peripheral blood and elevated cardiac enzymes. The coronary angiography showed normal coronary arteries. Single photon emission computed tomography (SPECT) showed infiltrative myocardial disease. She was then diagnosed with eosinophil infiltrations. Combined with peripheral nerve injury and lung involvement, she was diagnosed as having Churg-Strauss syndrome. After initiating prednisone treatment, her eosinophilia and rising cardiac enzymes recovered to normal, and both her echocardiographic abnormalities and symptoms noticeably improved.


Sujet(s)
Cardiomyopathie dilatée/diagnostic , Syndrome de Churg-Strauss/diagnostic , Éosinophilie/diagnostic , Myocardite/diagnostic , Adulte , Asthme/complications , Syndrome de Churg-Strauss/complications , Diagnostic différentiel , Échocardiographie , Éosinophilie/étiologie , Femelle , Humains , Myocardite/étiologie , Tomographie par émission monophotonique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...